Grail was founded in 2015 by Richard (Rick) Klausner, MD and Jeff Huber. The company filed its S-1 registration document with the SEC in September 2020 in advance of a planned Initial Public Offering. Subsequently in the same month, Illumia announced in a press release it had reached a definitive agreement to acquire Grail for $8 billion.

Grail is the developer of a pan-cancer screening test designed to detect cancer early. The company has raised approximately $2 billion in Venture Capital funding from investors including ARCH Venture Partners, Bezos Expeditions, Biomatics Capital, GV, Illumina, Foresite Capital Management, McKesson Ventures, Tencent, Amino Capital, Baillie Gifford, Decheng Capital, Dentsu Ventures, 6 Dimensions Capital, and Blue Pool Capital. Per company press releases, Grail last raised $390 million in May 2020 at a post-money valuation of $3.85 billion.

Register for Details

For more details on financing and valuation for Grail, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Who are Grail's major investors?

Sequoia Capital China
Canada Pension Plan Investment Board
SV Angel
PSP Investments
Hillhouse Capital Group
HuangPu River Capital

Grail Funding Rounds and IPO Valuation

Date Funding Round Funding Raised Price per Share IPO Valuation
5/6/2020 Series D $392.01MM raised $XXX.XX $XXX.XX
5/21/2018 Series C $300MM raised $XXX.XX $XXX.XX
11/22/2017 Series B $1.24B raised $XXX.XX $XXX.XX
1/8/2016 Series A $85MM raised $XXX.XX $XXX.XX
Based on primary financings
Powered by Forge Data

Learn more about Grail

Forge green plus iconForge green minus icon

What is Grail funding to date?

Grail has raised $2.02B to date.
Forge green plus iconForge green minus icon

When was Grail founded?

Grail was founded in 2016.
Updated on: Sep 1, 2022